Claims
- 1. A pharmaceutical composition for the treatment of a condition of the lower gastrointestinal tract by rectal or oral administration comprising a complex of an amide-type local anaesthetic and a polyacrylate together with a pharmaceutically acceptable carrier, diluent and/or excipient.
- 2. A composition as claimed in claim 1 wherein the polyacrylate is a carbomer.
- 3. A composition as claimed in claim 2 wherein the carbomer is carbopol 974P.
- 4. A composition as claimed in any one of claims 1 to 3 wherein the amide type anaesthetic is aptocaine, bupivacaine, butanilicaine, carticaine, cinchocaine, clibucaine, ethyl parapiperidinoacetylaminobenzoate, etidocaine, lignocaine, mepivacaine, oxethazaine, prilocaine, pyrrocaine, ropivacaine, tolycaine and vadocaine.
- 5. A composition as claimed in claim 4 wherein the amide type anaesthetic is lignocaine.
- 6. A composition as claimed in any one of claims 1 to 3 wherein the ratio of anaesthetic to polyacrylate is 0.5:1 to 10:1.
- 7. A composition as claimed in claim 6 wherein the ratio is 1:1 to 5:1.
- 8. A composition as claimed in claim 7 wherein the ratio is about 1:1 or about 5:1.
- 9. A pharmaceutical composition for the treatment of a condition of the lower gastrointestinal tract by rectal or oral administration comprising a complex of an amide-type local anaesthetic and a polyacrylate together with a pharmaceutically acceptable carrier, diluent and/or excipient in a delayed release oral form to deliver the complex post gastrically.
- 10. A composition as claimed in claim 9 which is in the form of an enterically coated capsule or tablet containing the complex, or an optionally enterically coated capsule or tablet containing enterically coated microgranules or power containing the complex.
- 11. A composition as claimed in claim 10 which is an enterically coated capsule containing the complex in a matrix of polygrycolised glycerides of hydrophilic and lipophilic value 53/10.
- 12. A composition as claimed in any one of claims 9 to 11 wherein the unit dosage of amide type anaesthetic in the complex is 100 mg to 200 mg.
- 13. A composition as claimed in claim 10 or 11 wherein the ratio of amide type anaesthetic to carbomer in the complex is 5:1.
- 14. A pharmaceutical composition for the treatment of a condition of the lower gastrointestinal tract by rectal or oral administration comprising a complex of an amide-type local anaesthetic and a polyacrylate together with a pharmaceutically acceptable carrier, diluent and/or excipient in a rectally administrable form.
- 15. A rectally administrable composition as claimed in claim 14 in the form of a liquid enema or foam enema, comprising a dosage of amide-type anaesthetic in the complex of 100 mg to 800 mg.
- 16. A composition as claimed in claim 15 wherein the ratio of anaesthetic to polyacrylate in the complex is about 1:1.
- 17. A composition as claimed in claim 15 or 16 which is an enema consisting essentially of about 400 mg lignocaine and about 400 mg carbomer in a complex, and aqueous preservative solution.
- 18. A method of relieving pain which comprises the step of administering a pharmaceutically effective amount of a complex of an amide-type local anaesthetic and a polyacrylate.
- 19. A method as claimed in claim 18 for the treatment or prophylaxis of a condition of the lower gastrointestinal tract.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9610862 |
May 1996 |
GBX |
|
Parent Case Info
This is A 371 of PCT/GB97/01420 filed May 23, 1997.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/GB97/01420 |
5/23/1997 |
|
|
5/3/1999 |
5/3/1999 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO97/44021 |
11/27/1997 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4954487 |
Cooper et al. |
Sep 1990 |
|
5589180 |
Hind |
Dec 1996 |
|
Non-Patent Literature Citations (2)
Entry |
Adams et al., J. Pharm. Pharmac., 25, 640-646, 1973. |
Chemical Abstracts, vol. 117, No. 26, David et al., 1992. |